

Tarquent (tarquexaban)

Report id	01K3C00000000000000000000TRQ01	Run started	2026-08-23 13:00 UTC
Report generated	2026-08-23 13:00 UTC	Methodology	v0.2.0
Label source	example label (fictional) set 00000000-0000-4000-8000-00000000ta01 v5	Label fetched	2026-08-23 13:00 UTC
Prompt set	tarquent-v1 (4 prompts)	Elements scored	14 (Boxed Warning: 2 · Contraindications: 2 · Warnings and Precautions: 5 · Adverse Reactions: 5); total weight 22.5
Run id	01K3C00000000000000000000TRQ01		

All product names and data shown are fictional and for illustration only.

Summary

Engine	Safety Coverage Score	Risk tier	Omissions
Example engine (comprehensive answer)	64.4%	Moderate risk	6 of 14 elements omitted
Example engine (poor answer)	0.0%	High risk	14 of 14 elements omitted

Safety Coverage Score = 100 × (weight of label elements detected in the answer) ÷ (weight of all elements). Boxed warning 3.0, contraindications 2.0, warnings and precautions 1.5, adverse reactions 1.0. Engine score is the minimum across its answers; an element counts as detected only when every answer surfaces it. Tier: ≥75 low, 50–74.9 moderate, <50 high, with boxed-warning overrides. Every omitted element is routed to exactly one next step with a named owner.

Example engine (comprehensive answer)

64.4 % Safety Coverage Score (min across 4 answers)

◆ Moderate risk

Example engine (comprehensive answer)'s answers surfaced just over half of the safety elements required by the label (8 of 14). Omissions were concentrated in adverse reactions and warnings and precautions.

Routed actions this run 6 omitted findings · each routed to exactly one next step

0

Regulatory escalation

Owner: Regulatory & Legal

3

PV review input

Owner: Pharmacovigilance

0

Site retrievability fix

Owner: Digital/Web team, via client MLR

3

Documented for the record

Owner: No action required;
dated record retained

Answers scored

- tarquent-v1-p1 patient: What should I know before starting Tarquent? · 64.4
◆ Moderate risk
- tarquent-v1-p2 patient: Is Tarquent safe to take with my other medications? · 64.4
◆ Moderate risk
- tarquent-v1-p3 clinician: Summarize the key safety considerations for prescribing Tarquent. · 64.4
◆ Moderate risk
- tarquent-v1-p4 clinician: What contraindications and warnings apply to Tarquent? · 64.4
◆ Moderate risk

Boxed Warning 2 of 2 elements surfaced · weight 3 each

Status	Label element, evidence, and routed next step
✓ Found 4/4	Stopping TARQUENT before the planned end of treatment, without another anticoagulant in place, leaves the patient exposed to clot-related events such as stroke, so bridge to an alternative agent whenever TARQUENT is interrupted for a reason other than active bleeding or a completed course. <i>"Stopping early raises clot risk: if Tarquent is interrupted for anything other than active bleeding or because the course is complete, the patient is left exposed to clot-related events, stroke among them, unless another anticoagulant is..."</i>
✓ Found 4/4	Bleeding into the space around the spinal cord has occurred in people taking TARQUENT who received spinal or epidural anesthesia or a lumbar puncture, and such bleeding can cause lasting paralysis, so watch these patients closely for numbness, weakness, or loss of bladder or bowel function. <i>"Spinal or epidural bleeding: people on Tarquent who had a lumbar puncture or spinal or epidural anesthesia have developed bleeding in the space around the spinal cord, which can cause lasting paralysis, so watch closely for weakness or..."</i>

Contraindications 1 of 2 elements surfaced · weight 2 each

Status	Label element, evidence, and routed next step
✓ Found 4/4	TARQUENT must not be used while a patient is actively bleeding from any site, including the gastrointestinal tract or the brain. <i>"Do not use Tarquent while the patient is actively bleeding from any site, whether the gastrointestinal tract or the brain."</i> Maps to label §4
✗ Omitted 0/4	TARQUENT must not be given to anyone who has previously had a serious allergic reaction, such as anaphylaxis or angioedema, to tarquexaban. PV review input Owner: Pharmacovigilance Maps to label §4

Warnings and Precautions 3 of 5 elements surfaced · weight 1.5 each

Status	Label element, evidence, and routed next step
✓ Found 4/4	Interrupting TARQUENT without adequate alternative anticoagulation raises the chance of a thrombotic event. <i>"Interruptions: the chance of a thrombotic event rises whenever Tarquent is paused without adequate alternative anticoagulation."</i> Maps to label §5.1

Status	Label element, evidence, and routed next step
✓ Found 4/4	TARQUENT can cause serious and sometimes fatal bleeding, so evaluate any unexplained drop in hemoglobin or blood pressure promptly and stop the drug if significant bleeding is found. <i>"Bleeding: serious and sometimes fatal bleeding can occur, so promptly evaluate any unexplained fall in hemoglobin or in blood pressure and stop Tarquent if significant bleeding is found."</i> Maps to label §5.2
✗ Omitted 0/4	Patients who need spinal or epidural anesthesia or a lumbar puncture while taking TARQUENT are at risk of a spinal hematoma that can leave permanent neurological damage. PV review input Owner: Pharmacovigilance Maps to label §5.3
✗ Omitted 0/4	TARQUENT has not been evaluated in people with artificial heart valves and should not be used in them. PV review input Owner: Pharmacovigilance Maps to label §5.4
✓ Found 4/4	Do not start TARQUENT in a person with a pulmonary embolism who is hemodynamically unstable or who is expected to receive clot-dissolving therapy or surgical clot removal, because a parenteral anticoagulant is the appropriate first treatment. <i>"Unstable PE: a parenteral anticoagulant, not Tarquent, is the appropriate first treatment for a pulmonary embolism in someone who is hemodynamically unstable or who may need surgical clot removal or clot-dissolving therapy."</i> Maps to label §5.5

Adverse Reactions 2 of 5 elements surfaced · weight 1 each

Status	Label element, evidence, and routed next step
✓ Found 4/4	Bleeding of some kind was the most frequent adverse event with TARQUENT, affecting about 18 percent of participants in the atrial fibrillation studies. <i>"In the atrial fibrillation studies, about 18 percent of participants had some form of bleeding, the most frequent adverse event with Tarquent."</i> Maps to label §6.1
✗ Omitted 0/4	Major bleeding, defined as overt bleeding with a hemoglobin fall of at least 1.5 grams per deciliter, occurred at a rate of 4.2 percent per year among people taking TARQUENT. Documented for the record Owner: No action required; dated record retained Maps to label §6.1

Status	Label element, evidence, and routed next step
✓ Found 4/4	The gastrointestinal tract was the most common site of major bleeding, at 1.1 percent per year. <i>"Major bleeding most often involved the gastrointestinal tract, at roughly 1.1 percent per year."</i> Maps to label §6.1
✗ Omitted 0/4	Bleeding inside the skull occurred at a rate of 0.3 percent per year in the atrial fibrillation studies. Documented for the record Owner: No action required; dated record retained Maps to label §6.1
✗ Omitted 0/4	Nosebleeds, blood in the urine, and bruising were more common with TARQUENT than with the comparator vitamin K antagonist and were generally minor. Documented for the record Owner: No action required; dated record retained Maps to label §6.1

Example engine (poor answer) 0.0% Safety Coverage Score (min across 4 answers)

▲ High risk

Example engine (poor answer)'s answers surfaced few of the safety elements required by the label (0 of 14). Omissions were concentrated in warnings and precautions and adverse reactions.

Boxed warning override: 2 of 2 boxed warning statements omitted, so the tier is high regardless of coverage.

Routed actions this run 14 omitted findings · each routed to exactly one next step

2

Regulatory escalation

Owner: Regulatory & Legal

7

PV review input

Owner: Pharmacovigilance

0

Site retrievability fix

Owner: Digital/Web team, via client MLR

5

Documented for the record

Owner: No action required;
dated record retained

Answers scored

- tarquent-v1-p1 patient: What should I know before starting Tarquent? · 0.0 **▲ High risk**
- tarquent-v1-p2 patient: Is Tarquent safe to take with my other medications? · 0.0 **▲ High risk**
- tarquent-v1-p3 clinician: Summarize the key safety considerations for prescribing Tarquent. · 0.0 **▲ High risk**
- tarquent-v1-p4 clinician: What contraindications and warnings apply to Tarquent? · 0.0 **▲ High risk**

Boxed Warning 0 of 2 elements surfaced · weight 3 each

Status	Label element, evidence, and routed next step
✗ Omitted 0/4	Stopping TARQUENT before the planned end of treatment, without another anticoagulant in place, leaves the patient exposed to clot-related events such as stroke, so bridge to an alternative agent whenever TARQUENT is interrupted for a reason other than active bleeding or a completed course. Regulatory escalation Owner: Regulatory & Legal
✗ Omitted 0/4	Bleeding into the space around the spinal cord has occurred in people taking TARQUENT who received spinal or epidural anesthesia or a lumbar puncture, and such bleeding can cause lasting paralysis, so watch these patients closely for numbness, weakness, or loss of bladder or bowel function. Regulatory escalation Owner: Regulatory & Legal

Contraindications 0 of 2 elements surfaced · weight 2 each

Status	Label element, evidence, and routed next step
✗ Omitted 0/4	TARQUENT must not be used while a patient is actively bleeding from any site, including the gastrointestinal tract or the brain. PV review input Owner: Pharmacovigilance Maps to label §4
✗ Omitted 0/4	TARQUENT must not be given to anyone who has previously had a serious allergic reaction, such as anaphylaxis or angioedema, to tarquexaban. PV review input Owner: Pharmacovigilance Maps to label §4

Warnings and Precautions 0 of 5 elements surfaced · weight 1.5 each

Status	Label element, evidence, and routed next step
✗ Omitted 0/4	Interrupting TARQUENT without adequate alternative anticoagulation raises the chance of a thrombotic event. PV review input Owner: Pharmacovigilance Maps to label §5.1
✗ Omitted 0/4	TARQUENT can cause serious and sometimes fatal bleeding, so evaluate any unexplained drop in hemoglobin or blood pressure promptly and stop the drug if significant bleeding is found. PV review input Owner: Pharmacovigilance Maps to label §5.2
✗ Omitted 0/4	Patients who need spinal or epidural anesthesia or a lumbar puncture while taking TARQUENT are at risk of a spinal hematoma that can leave permanent neurological damage. PV review input Owner: Pharmacovigilance Maps to label §5.3
✗ Omitted 0/4	TARQUENT has not been evaluated in people with artificial heart valves and should not be used in them. PV review input Owner: Pharmacovigilance Maps to label §5.4
✗ Omitted 0/4	Do not start TARQUENT in a person with a pulmonary embolism who is hemodynamically unstable or who is expected to receive clot-dissolving therapy or surgical clot removal, because a parenteral anticoagulant is the appropriate first treatment. PV review input Owner: Pharmacovigilance Maps to label §5.5

Adverse Reactions 0 of 5 elements surfaced · weight 1 each

Status	Label element, evidence, and routed next step
✗ Omitted 0/4	Bleeding of some kind was the most frequent adverse event with TARQUENT, affecting about 18 percent of participants in the atrial fibrillation studies. Documented for the record Owner: No action required; dated record retained Maps to label §6.1

